Phase I trial of IDX 19368.
Phase of Trial: Phase I
Latest Information Update: 04 Feb 2013
At a glance
- Drugs IDX 19368 (Primary)
- Indications Hepatitis
- Focus Adverse reactions; Pharmacokinetics
- 04 Feb 2013 The development programme for IDX 19368 has been discontinued following a communication from the US FDA indicating that the programme will remain in clinical hold according to an Idenix media release. Patient dosing had not been initiated.
- 04 Feb 2013 Status changed from suspended to discontinued based on information reported in an Idenix media release.
- 27 Aug 2012 Status changed from planning to suspended.